Rethinking CMV Management Post-HSCT: What Would You Change?

Program Overview

Cytomegalovirus (CMV) remains one of the most significant threats following allogenic hematopoietic stem cell transplantation (HSCT). Effective prevention and management are central to improving patient outcomes, particularly with increasing antiviral resistance. In this activity, Drs. Fareed Khawaja and Michelle Yong discuss 2 cases by breaking them down step-by-step and challenging learners to critically assess clinical decisions and identify opportunities for improvement. Through these discussions, participants will gain practical insights into optimizing CMV management strategies in line with the latest evidence and guideline-based recommendations.

0.75 CE Credit(s)
Expires: September 2, 2027

Target Audience

Transplant specialists, hematologists, hematologists/oncologists, internal medicine, and infectious disease clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Translate current cytomegalovirus (CMV) guidelines into evidence‑based prevention plans for patients post-hematopoietic stem cell transplant (HSCT)
  • Integrate safety considerations and guideline recommendations into the care of patients with resistant/refractory CMV post‑HSCT

Activity Faculty

62-26-1964-VL-001 Fareed GHL

Fareed Khawaja, MBBS

Associate Professor, Department of Infectious Diseases,
Infection Control and Employee Health, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

62-26-1964-VL-001 young

Michelle Yong, MBBS, PhD, FRACP, MPH

Associate Professor, Department of Infectious Diseases
ID Physician and Post-doc Researcher
Royal Melbourne Hospital and Peter MacCallum Cancer Centre
University of Melbourne
National Centre for Infections in Cancer NCIC
Victoria, Australia

Supporter Statement

Supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Provider Statement

Jointly provided by Partners for Advancing Clinical Education and RMEI Medical Education, LLC 

Disclosure of Financial Relationships

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Fareed Khawaja, MBBS, has relevant financial relationship(s) with Merck, Symbio, Viracor-Eurofins (Grant/Research Support).

Michelle Yong, MBBS, PhD, FRACP, MPH, has relevant financial relationship(s) with Merck (Grant/Research Support); Alexion, Gilead, GSK, Takeda (Speaker).

Planners and Managers

All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and RMEI Medical Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation 

Physician Continuing Medical Education 
Partners designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education 
Partners designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008073-9999-26-196-H01-P)
Type of Activity: Knowledge

Method of Participation and Request for Credit

Participation in this self-study activity should be completed in approximately 0.75 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps.

Users must:

  • Review the objectives and disclosures
  • Study the educational content
  • Successfully complete the Post-test
  • Complete the Evaluation

You must receive a test score of at least 75% and respond to all Evaluation questions to receive a certificate.

For Pharmacists: Upon successfully completing the Post-test with a score of 75% or better and the online Evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Your Feedback is Important!

As a sign of gratitude for providing vital outcomes data used for the development of future educational programming, you will be entered into a drawing for a $100 Amazon gift card!*

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

This incentive is managed by the joint providers, Partners for Advancing Clinical Education (Partners) and RMEI Medical Education, LLC (RMEI). For participants who meet eligibility criteria (ie, completion of the evaluation form and providing contact information), RMEI will select the winner(s) via automated random drawing on a quarterly basis from among all eligible entries and will be notified through the contact information provided. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Contact Information

If you have questions about this activity, please contact RMEI at [email protected]

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2026. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources